[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100403661":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":52,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Changhai Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"pancreatic mass diagnosed benign",null,"Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with benign pancreatic mass.",[13],"Diagnostic Test: Endoscopic Ultrasound (EUS), Fine Needle Aspiration",{"label":15,"type":10,"description":16,"interventionNames":17},"pancreatic mass diagnosed malignant","Through pathological examination, radiological examination and follow-up, these patients are finally diagnosed with pancreaitic cancer.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DIAGNOSTIC_TEST","Endoscopic Ultrasound (EUS), Fine Needle Aspiration","Endoscopic Ultrasound (EUS), Fine Needle Aspiration, which are routine clinical operations",[9,15],[25],{"name":26,"affiliation":5,"role":27},"Kaixuan Wang, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":10,"email":33},"Xiangyu Kong, MD","CONTACT","13564644397","xiangyukong185@hotmail.com",[35],{"facility":5,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Shanghai","Shanghai Municipality","200433","China","CN",{"type":43,"coordinates":44},"Point",[45,46],121.45806,31.22222,{"lat":46,"lon":45},[49],{"name":26,"role":31,"phone":50,"phoneExt":10,"email":51},"86-21-31161353","wangkaixuan224007@sina.com",{"type":27,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Zhaoshen Li","Prefessor of Department of Gastroenterology","100403661","establish-diagnostic-models-based-on-portal-venous-blood-for-pancreatic-cancer-100403661",false,"NCT04536220","Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer","Establish a Diagnostic Model Based on Multiple Molecule Profiling and Certain Established Markers for Identification of Pancreatic Cancer","Inclusion Criteria:\n\n1. age 18-75 years,male or female\n2. diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI)\n3. lesion diameter larger than 1 cm\n4. signed informed consent letter\n\nExclusion Criteria:\n\n1. pregnant female\n2. Pancreatic cystic lesions\n3. Anticoagulant\u002Fantiplatelet therapy cannot be suspended\n4. unable or refuse to provide informed consent\n5. Coagulopathy (platelet count \\\u003C 50× 103\u002FμL,international normalized ratio \\> 1.5)\n6. Severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia\n7. with history of mental disease\n8. other medical conditions that are not suitable for EUS-FNA","ALL","18 Years","80 Years",{"count":66,"type":67},300,"ESTIMATED","OBSERVATIONAL","Explore new markers based on portal venous blood sampling to establish novel diagnostic models for identification of malignant pancreatic mass.",[71],"Diagnoses Disease",[73],"diagnosis and pancreatic cancer","2024-03-28",{"date":76,"type":77},"2024-03-29","ACTUAL",{"date":79,"type":77},"2024-01-01",{"date":81,"type":67},"2026-07-30",{"name":5,"class":6},1]